The authors of this systematic review have not only aimed to establish the incidence of hypertension associated with a multicystic dysplastic kidney (MCDK) but have also tried to determine the malignancy risk associated with an MCDK and assess the rate of MCDK involution.

It is a well-conducted systematic review with a view to address the lack of a standardised protocol for the investigation and non-operative management of paediatric MCDK. Institutional protocols for non-operative management remain essentially ad hoc.

The review was performed on all relevant studies published between 1968 and April 2017 using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies were identified by specific inclusion and exclusion criteria, all of which included data relevant to the outcomes. Hypertension was defined as systolic blood pressure greater than the 95th centile for gender, age and height centile. Subset analysis was performed for hypertension associated with an MCDK.

The primary outcome measure revealed a 3.2% (27/838) risk of developing hypertension associated with an MCDK. The secondary outcome measure noted a 0.07% malignancy risk (2/2820). The tertiary outcome measure established that 53.3% (1502/2820) had evidence of involution of the dysplastic kidney. A total of 44 cohort studies (2820 patients) were analysed.

They concluded that given the low risk of hypertension and malignancy, which is similar to the general population, the current conservative non-operative pathway is an appropriate management strategy. They have also proposed an algorithm to help support clinicians with ongoing management.

Evidence-based treatment of multicystic dysplastic kidney: a systematic review.
Chang D, Sivananthan RM, Nataraja L, et al.
Share This
Ravindar Anbarasan

Southampton Children’s Hospital.

View Full Profile